Trial Profile
Icotinib With Concurrent Radiotherapy Versus Etoposide/Cisplatin With Concurrent Radiotherapy in Stage III Non-small Cell Lung Cancer With EGFR 19/21 Mutation
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 02 Nov 2022
Price :
$35
*
At a glance
- Drugs Icotinib (Primary) ; Cisplatin; Etoposide
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Sponsors Betta Pharmaceuticals Co Ltd
- 20 Aug 2014 New trial record